In 1947, DES finally gained FDA approval for prescription to pregnant women who had diabetes as a method of preventing miscarriages. This led to the widespread prescription of DES to all pregnant women.In 1971, the FDA recommended against the prescription of DES to pregnant women. As a result, DES then began to see a withdraw from the US market starting in 1972 and in the European market starting in 1978, but the FDA still did not withdraw its approval for the use of DES in humans.DES was classified as a Group 1 carcinogen by the International Agency for Research on Cancer. After classification as a carcinogen, DES had its FDA approval withdrawn in 2000. DES is currently only in use for veterinary practices and in research trials as allowed by the FDA.Medical Ethics
Medical Ethics in regard to the approval and use of Diethylstilbestrol have been dismissed because of the actions of the FDA and pharmaceutical companies that were making DES at the time of its use. The Vice President of the American Drug Manufacturers Association, Carson Frailey, was employed by drug companies creating DES in order to help get it approved by the Food and Drug Administration (FDA). Nancy Langston, the author of The Retreat from Precaution: Regulating Diethylstilbestrol (DES), Endocrine Disruptors, and Environmental Health, states that "Frailey persuaded fifty-four doctors from around the country to write to the FDA, describing their clinical experiences with a total of more than five thousand patients.
Simeticone (INN), also known as simethicone (USAN), is an anti-foaming agent used to reduce bloating, discomfort or pain caused by excessive gas. Medical uses
Simeticone is used to relieve the symptoms of excessive gas in the gastrointestinal tract, namely bloating, burping, and flatulence. While there is a lack of conclusive evidence that simeticone is effective for this use, ⁣ studies have shown that it can relieve symptoms of functional dyspepsia and functional bloating.It has not been fully established that simeticone is useful to treat colic in babies, and it is not recommended for this purpose. A study in the United Kingdom reported that according to parental perception simeticone helped infant colic in some cases.Simeticone can also be used for suspected postoperative abdominal discomfort in infants. Side effects
Simeticone does not have any serious side effects. Two uncommon side effects (occurring in 1 in 100 to 1 in 1,000 patients) are constipation and nausea. Pharmacology
Simeticone is a non-systemic surfactant which decreases the surface tension of gas bubbles in the GI tract. This allows gas bubbles to leave the GI tract as flatulence or belching. Simeticone does not reduce or prevent the formation of gas. Its effectiveness has been shown in several in vitro studies. Chemistry
Simethicone is a mixture of dimethicone and silicon dioxide. Names
The INN name is "simeticone", which was added to the INN recommended list in 1999.Simeticone is marketed under many brand names and in many combination drugs; it is also marketed as a veterinary drug. == References ==